FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080551092> ?p ?o ?g. }

• W2080551092 endingPage "1070" @default.
• W2080551092 startingPage "1065" @default.
• W2080551092 abstract "1. The nature of the binding site mediating the insulin secretagogue activity of certain imidazoline compounds remains unclear and the pharmacology of the I1- and I2-imidazoline sites, described in many tissues, does not correlate with the observed responses to imidazolines in islets. In the present paper, we describe further results which support the concept that the islet imidazoline site may represent a novel subtype of imidazoline receptor. 2. Culture of rat isolated islets in the presence of imidazoline secretagogues (either efaroxan or phentolamine) resulted in loss of responsiveness on subsequent re-exposure to these agents. However, culture of islets with either idazoxan or UK14,304 (imidazoline ligands that do not stimulate insulin secretion) did not lead to any loss of response when the islets were subsequently exposed to efaroxan. By contrast, islets cultured with UK14,304 (a potent alpha 2-adrenoceptor agonist), displayed loss of sensitivity to noradrenaline, consistent with down-regulation of alpha 2-adrenoceptors. 3. In order to characterize the imidazoline site further, radioligand binding studies were performed in membranes from RINm5F insulinoma cells using [3H]-RX821002, an imidazoline insulin secretagogue that does not interact significantly with imidazoline sites in other tissues. [3H]-RX821002 labelled alpha 2-adrenoceptors with high affinity (2.01 +/- 0.7 nM) but also labelled a second, non-adrenoceptor site with much lower affinity. 4. Under conditions of alpha 2-adrenoceptor blockade (in the presence of adrenaline), efaroxan displaced [3H]-RX821002 binding to the low affinity site, in a dose-dependent manner. Competition studies employing additional imidazoline compounds of varying secretagogue activity revealed that the pharmacological profile of the low affinity site correlates well with that observed in secretion experiments.5. The results obtained from the down-regulation experiments with isolated islets and from the radioligand binding studies suggest that the low affinity [3H]-RX821002 binding site may represent the functional receptor responsible for the secretagogue activity of imidazoline compounds in the endocrine pancreas and that it has a pharmacological profile distinct from those of I,- and 12-sites." @default.
• W2080551092 created "2016-06-24" @default.
• W2080551092 creator A5035490035 @default.
• W2080551092 creator A5048879058 @default.
• W2080551092 creator A5049285409 @default.
• W2080551092 creator A5052656352 @default.
• W2080551092 date "1994-08-01" @default.
• W2080551092 modified "2023-10-17" @default.
• W2080551092 title "The imidazoline site involved in control of insulin secretion: characteristics that distinguish it from I1- and I2-sites" @default.
• W2080551092 cites W155719924 @default.
• W2080551092 cites W1849954389 @default.
• W2080551092 cites W1964952258 @default.
• W2080551092 cites W1965362290 @default.
• W2080551092 cites W1978236712 @default.
• W2080551092 cites W1985318550 @default.
• W2080551092 cites W1997374474 @default.
• W2080551092 cites W1997607044 @default.
• W2080551092 cites W2020776311 @default.
• W2080551092 cites W2032996897 @default.
• W2080551092 cites W2043218865 @default.
• W2080551092 cites W2049352533 @default.
• W2080551092 cites W2051028721 @default.
• W2080551092 cites W2055943620 @default.
• W2080551092 cites W2061379613 @default.
• W2080551092 cites W2061729281 @default.
• W2080551092 cites W2063478961 @default.
• W2080551092 cites W2071144121 @default.
• W2080551092 cites W2072598497 @default.
• W2080551092 cites W2076099286 @default.
• W2080551092 cites W2077496709 @default.
• W2080551092 cites W2086965319 @default.
• W2080551092 cites W2089278729 @default.
• W2080551092 cites W2092879381 @default.
• W2080551092 cites W2113424951 @default.
• W2080551092 cites W219986296 @default.
• W2080551092 cites W2219816266 @default.
• W2080551092 cites W2265790923 @default.
• W2080551092 cites W2321695982 @default.
• W2080551092 cites W2403550797 @default.
• W2080551092 cites W3027184292 @default.
• W2080551092 cites W4232534952 @default.
• W2080551092 doi "https://doi.org/10.1111/j.1476-5381.1994.tb13191.x" @default.
• W2080551092 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1910228" @default.
• W2080551092 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7952865" @default.
• W2080551092 hasPublicationYear "1994" @default.
• W2080551092 type Work @default.
• W2080551092 sameAs 2080551092 @default.
• W2080551092 citedByCount "103" @default.
• W2080551092 countsByYear W20805510922012 @default.
• W2080551092 countsByYear W20805510922013 @default.
• W2080551092 countsByYear W20805510922014 @default.
• W2080551092 countsByYear W20805510922015 @default.
• W2080551092 countsByYear W20805510922016 @default.
• W2080551092 countsByYear W20805510922017 @default.
• W2080551092 countsByYear W20805510922019 @default.
• W2080551092 countsByYear W20805510922020 @default.
• W2080551092 countsByYear W20805510922021 @default.
• W2080551092 countsByYear W20805510922022 @default.
• W2080551092 crossrefType "journal-article" @default.
• W2080551092 hasAuthorship W2080551092A5035490035 @default.
• W2080551092 hasAuthorship W2080551092A5048879058 @default.
• W2080551092 hasAuthorship W2080551092A5049285409 @default.
• W2080551092 hasAuthorship W2080551092A5052656352 @default.
• W2080551092 hasBestOaLocation W20805510921 @default.
• W2080551092 hasConcept C123605464 @default.
• W2080551092 hasConcept C126322002 @default.
• W2080551092 hasConcept C134018914 @default.
• W2080551092 hasConcept C170493617 @default.
• W2080551092 hasConcept C185592680 @default.
• W2080551092 hasConcept C2776885963 @default.
• W2080551092 hasConcept C2777014715 @default.
• W2080551092 hasConcept C2778938600 @default.
• W2080551092 hasConcept C2779306644 @default.
• W2080551092 hasConcept C2780161494 @default.
• W2080551092 hasConcept C2780253649 @default.
• W2080551092 hasConcept C2780307058 @default.
• W2080551092 hasConcept C2780648677 @default.
• W2080551092 hasConcept C2780939551 @default.
• W2080551092 hasConcept C55493867 @default.
• W2080551092 hasConcept C71924100 @default.
• W2080551092 hasConcept C86803240 @default.
• W2080551092 hasConceptScore W2080551092C123605464 @default.
• W2080551092 hasConceptScore W2080551092C126322002 @default.
• W2080551092 hasConceptScore W2080551092C134018914 @default.
• W2080551092 hasConceptScore W2080551092C170493617 @default.
• W2080551092 hasConceptScore W2080551092C185592680 @default.
• W2080551092 hasConceptScore W2080551092C2776885963 @default.
• W2080551092 hasConceptScore W2080551092C2777014715 @default.
• W2080551092 hasConceptScore W2080551092C2778938600 @default.
• W2080551092 hasConceptScore W2080551092C2779306644 @default.
• W2080551092 hasConceptScore W2080551092C2780161494 @default.
• W2080551092 hasConceptScore W2080551092C2780253649 @default.
• W2080551092 hasConceptScore W2080551092C2780307058 @default.
• W2080551092 hasConceptScore W2080551092C2780648677 @default.
• W2080551092 hasConceptScore W2080551092C2780939551 @default.
• W2080551092 hasConceptScore W2080551092C55493867 @default.
• W2080551092 hasConceptScore W2080551092C71924100 @default.
• W2080551092 hasConceptScore W2080551092C86803240 @default.

• next